July 07, 2026 09:23 ET  | Source: Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review […]

July 07, 2026 09:12 ET  | Source: Alamar Biosciences, Inc. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program Data to

July 07, 2026 09:07 ET  | Source: King Faisal Specialist Hospital & Research Centre JEDDAH, Kingdom of Saudi Arabia, July 07, 2026 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre in Jeddah has successfully developed and implemented the world’s first protocol of its kind, using an algorithm to accurately estimate the expected stem cell yield

Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani July 07, 2026 07:35 ET  | Source: Vivani Medical, Inc. ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a

July 07, 2026 07:00 ET  | Source: Teva Pharmaceutical Industries Ltd Teva will hold an investor call and live webcast today,Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data. TEL AVIV, Israel, July 07, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an

July 06, 2026 10:00 ET  | Source: Aztiq Consulting ehf. REYKJAVIK, Iceland, July 06, 2026 (GLOBE NEWSWIRE) — Aztiq today announced the promotion of David Olafsson, Danny Major and Eunsun Choi to Partner, recognizing their significant contributions to Aztiq’s growth, investment activities and long-term value creation across the healthcare ecosystem. Aztiq is an investment company focused on

July 02, 2026 10:45 ET  | Source: Allwyn The F1® Allwyn Global Community Award 2026 trophy presented to Jonny Wright and Laura Walsh from winning local charity Starlight Children’s Foundation at the FORMULA 1® PIRELLI BRITISH GRAND PRIX 2026 at Silverstone, UK. SILVERSTONE, United Kingdom, July 02, 2026 (GLOBE NEWSWIRE) — Starlight Children’s Foundation has been named

July 01, 2026 20:43 ET  | Source: Junshi Biosciences SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has recently entered into a license agreement with Fosun Wanbang Pharma

New collaboration delivers streamlined integration from drug substance to drug product, including sterile fill-finish and device assembly for clinical programs. June 30, 2026 12:00 ET  | Source: AGC Biologics, Inc. SEATTLE, June 30, 2026 (GLOBE NEWSWIRE) — Drug developers have a new, optimized option for U.S.-based manufacturing, as AGC Biologics enters a strategic partnership with Pyramid Pharma

June 30, 2026 08:30 ET  | Source: Kyowa Kirin PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) — Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome

June 29, 2026 09:00 ET  | Source: Optimi Health Corp. Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025. VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi”), a

June 29, 2026 08:30 ET  | Source: Kyowa Kirin PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced positive results from PROSPER, a real-world observational study of mogamulizumab in adults with mycosis fungoides (MF) or Sézary syndrome (SS). In the study, patients

June 29, 2026 06:00 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc.

Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global Innovation June 25, 2026 09:00 ET  | Source: Evaluate LONDON, June 25, 2026 (GLOBE NEWSWIRE) — Evaluate, a Norstella company and the leading global provider of market insights for the pharmaceutical industry, today announced that Ask Ella has been named “Enterprise AI Search Solution of the Year”

June 23, 2026 09:03 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., June 23, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced the launch of SKyvec™, its proprietary, multimodal viral vector platform. Designed to support gene therapy programs at every stage, from early research through clinical supply and commercial manufacturing, the SKyvec™ platform integrates development capabilities with global